Skip to main content
main-content

01.12.2018 | Short report | Ausgabe 1/2018 Open Access

Antimicrobial Resistance & Infection Control 1/2018

Colonization sites in carriers of ESBL-producing Gram-negative bacteria

Zeitschrift:
Antimicrobial Resistance & Infection Control > Ausgabe 1/2018
Autoren:
Joffrey van Prehn, Anna M. Kaiser, Suzanne D. van der Werff, Rosa van Mansfeld, Christina M. J. E. Vandenbroucke-Grauls

Abstract

Objective

The distribution of Extended-Spectrum Beta-Lactamase-producing Gram-negative bacteria (ESBL-GNB) colonization sites is relevant for infection control guidelines on detection and follow-up of colonization. We questioned whether it is possible to rely solely on rectal swab culture for follow-up of ESBL-GNB colonization.

Methods

We retrospectively assessed ESBL-GNB colonization sites in patients in a tertiary hospital in the Netherlands. The Laboratory Information Management System was queried for all bacterial cultures obtained between January 2012 and August 2016. All patients with one or more cultures positive for ESBL-GNB were identified and the distribution of ESBL-GNB positive sample sites was assessed. A subgroup analysis was performed on patients for whom at least one rectal swab specimen was available.

Results

We identified 1011 ESBL-GNB carriers with 16,578 specimens for analysis. ESBL-GNB were most frequently isolated from the rectum (506/1011), followed by the urogenital (414/1011) and respiratory tract (142/1011), and pus (136/1011). For 588 patients at least one rectal swab specimen was available. In this subgroup, ESBL-GNB colonization was detected only in the rectum in 55.4% (326/588) of patients, in 30.6% (180/588) in the rectum and a different culture site, and in 13.9% (82/588) no rectal colonization was detected.

Conclusions

Rectal colonization with ESBL-GNB was detected in 86% of ESBL-GNB carriers. However, in 14% of ESBL-GNB carriers we did not detect rectal colonization. Therefore, samples taken for follow-up of colonization with multi-drug resistant Gram-negative bacteria (MDR-GNB) should ideally also include samples from the site where the MDR-GNB was initially found.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Antimicrobial Resistance & Infection Control 1/2018 Zur Ausgabe